NPAS2 and prostate carcinoma: This SNP might affect prostate cancer progression by reducing the expression level of NPAS2. Thus, our findings might help to improve understanding of the interaction of circadian dysfunction and prostate cancer progression, and can provide a promising biomarker toward realizing the personalized management of patients with prostate cancer.